C-Path Launches RDCA-DAP to Accelerate Rare Disease Treatments
The Critical Path Institute (C-Path), an FDA-sponsored initiative, has launched the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). This platform aims to speed up treatment innovation for rare diseases by sharing patient data, currently estimated to be over 7,000 diseases, with more than 90% having no FDA-approved treatment.
RDCA-DAP integrates rare disease data from clinical trials, observational studies, patient registries, and real-world data, providing workspaces for advanced analytics. Interested parties can access this data by finding datasets of interest and requesting access. The platform, introduced at the RDCA-DAP 2021 Virtual Workshop, encourages further research and lowers costs by making disease data from multiple organizations worldwide more accessible.
The initiative is a partnership between the National Organization for Rare Disorders (NORD), C-Path, and the U.S. Food and Drug Administration (FDA). It seeks to address bottlenecks in drug development for rare diseases by promoting collaboration and candid dialogue. RDCA-DAP curates data to find solutions to these bottlenecks and demonstrates its importance to academic, clinical, regulatory, and patient groups.
To submit rare disease data to RDCA-DAP, interested parties can contact the project team at [email protected] or visit c-path.org/programs/rdca-dap and rarediseases.org/rdca-dap. By sharing data and promoting collaboration, RDCA-DAP hopes to bring attention to relatively neglected diseases and accelerate the development of effective treatments.
